Celltrion accelerates Japan push with newly approved biosimilars

Celltrion announced Friday that it has obtained product approval from the Japanese Ministry of Health, Labor and Welfare for Omlyclo, a biosimilar of allergic disease treatment Xolair, and Eydenzelt, a biosimilar of the ophthalmic disease treatment Eylea. This is an opportunity to further strengthen our influence in the Japanese market, an official from Celltrion said. Based on the performance of our existing flagship lineup, we will do our best to facilitate the early adoption of our latest